The PREVENT-AD (Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease) cohort is composed of cognitively healthy participants over 55 years old, at risk of developing Alzheimer Disease (AD) as their parents and/or siblings were/are affected by the disease. These ‘at-risk’ participants have been followed for a naturalistic study of the presymptomatic phase of AD since 2011 using multimodal measurements of various disease indicators. Two clinical trials intended to test pharmaco-preventive agents have also been conducted. The PREVENT-AD research group is now releasing data openly with the intention to contribute to the community’s growing understanding of AD pathogenesis.

Additional details available in the PSC Bridges-2 Data Collections User Guide.